Company Overview of Neurovance, Inc.
Neurovance, Inc. develops pharmaceutical preparations for the treatment of disorder of the central nervous system. The company was founded in 2011 and is based in Cambridge, Massachusetts.
43 Thorndike Street
Cambridge, MA 02141
Founded in 2011
Key Executives for Neurovance, Inc.
Vice President of Clinical Development
Compensation as of Fiscal Year 2014.
Neurovance, Inc. Key Developments
Neurovance Appoints Brigitte Robertson as VP of Clinical Development
Aug 14 14
Neurovance announced that Brigitte Robertson, MD, has been appointed Vice President of Clinical Development. The company said that Dr. Robertson brings the Company nearly 20 years of expertise as a board certified adult, child and adolescent psychiatrist specializing in attention deficit hyperactivity disorder (ADHD), with over 15 years of clinical development experience focused on ADHD treatments. Most recently, Dr. Robertson served as Global Development Strategy Team Lead, Senior Director at Shire Pharmaceuticals.
Neurovance Appoints Brigitte Robertson as Vice President, Clinical Development
Aug 5 14
Neurovance, Inc. announced that Brigitte Robertson, MD, has been appointed as Vice President of Clinical Development. Most recently, Dr. Robertson served as Global Development Strategy Team Lead, Senior Director at Shire Pharmaceuticals, where she led multiple cross-functional global development teams and was accountable for the development strategy and execution for several development programs in ADHD involving Intuniv, SPD465 and Vyvanse, the leading ADHD franchise worldwide. Dr. Robertson will contribute to the development of Neurovance's centanafadine SR (formerly EB-1020 SR), a non-stimulant being developed for the treatment of adults with ADHD. She joins Neurovance with significant clinical and industry experience including senior roles at CCP Children's Hospital in San Diego, and Glaxo and Sepracor.
Neurovance Intends to Initiate a Human Abuse Liability (HAL) Study
Apr 3 14
Neurovance, Inc. announced that it has closed a $6.3 million extension to its series A1 financing round to further advance development of EB-1020 SR, a non-stimulant, for the treatment of all subtypes of adult ADHD (attention deficit hyperactivity disorder). Neurovance also announced that it intends to initiate a human abuse liability (HAL) study that will seek to confirm that EB-1020 has less abuse potential than the standard stimulant used presently. Interim data from the Neurovance phase 2a adult ADHD pilot study disclosed in January showed a statistically significant improvement in symptoms with a 21 point change in the primary endpoint, the ADHD-Rating Scale-IV score after 4 weeks of treatment (p<0.0001). Final data from the completed phase 2a pilot study including key secondary assessments on executive function, emotional dysregulation and level of function as well as detailed safety data, will be presented at the Late Breaking Sessions at the Society for Biological Psychiatry annual meeting on May 8. Adult ADHD is a serious medical condition. A recent study showed drivers with ADHD are nearly 50% more likely to be in a serious car crash. The impulsivity associated with ADHD contributes to adults with ADHD experiencing a higher rate of problems ranging from being fired from a job to unwanted pregnancies to incarceration. Adult ADHD is often associated with serious psychiatric comorbidities including depression, anxiety and substance abuse. Approximately 10 million adults in the US have ADHD, however, according to the National Institute of Mental Health, only one in 10 is receiving treatment. According to IMS Health, the US ADHD market is nearly evenly split between adults and children in terms of prescriptions at 26M and 25M total prescriptions, respectively. Although Neurovance is initially focused on adults because of the paucity of products available for adults and the rapid growth rate among the adult segment (prescriptions growing at 16% per year) Neurovance plans to expand its development to include adolescents and children once EB-1020 SR has been demonstrated safe and effective in adults. The EB-1020 Human Abuse Liability study will be a single-dose, randomized, double-blind, placebo- and active-controlled crossover study to evaluate the abuse potential of EB-1020 in healthy recreational stimulant users.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|